This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Alzheimer’s Therapeutics Market

Market Insights on Alzheimer's Therapeutics covering sales outlook, demand forecast & up-to-date key trends

Alzheimer's Therapeutics Market By Drug Name (Donepezil, Rivastigmine, Memantine, Galantamine, Manufactured Combination of Memantine And Donepezil), Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Manufactured Combination) & Region - Forecast 2022 - 2032

Alzheimer’s Therapeutics Market Outlook (2022-2032)

[363 Pages Report] The global Alzheimer’s therapeutics market is set to witness a valuation of US$ 2.8 Bn in 2022, and further expand at a CAGR of 9.3% to reach US$ 6.8 Bn by the year 2032. According to the recent study by Future Market Insights, Donepezil is leading the market by drug with a share of 68.4% in 2021 within the global market.

Data Points

Market Insights

Market Value 2021

US$ 2.6 Bn

Market Value 2022

US$ 2.8 Bn

Market Value 2032

US$ 6.8 Bn

CAGR 2022-2032

9.3%

Market Share of Top 5 Countries

62.3%

Alzheimer’s therapeutics holds approximately 2.4% of the overall US$ 109 Bn global target therapeutics market in 2021.

The global prevalence rate of Alzheimer’s is increasing because of factors like the increasing life expectancy, rise in the ageing population, and changes in lifestyles, among others. This will drive the Alzheimer’s therapeutics market in the coming years.

According to the World Health Organization (WHO), approximately 50 million individuals have Alzheimer’s disease in 2021, and there are nearly 10 million new cases recorded each year.

The total cost of Alzheimer's disease is increasing because of costly treatments and therapies which are being employed for Alzheimer’s disease management. According to the National Library of Medicine, it is projected that the cost of Alzheimer's disease to the global economy is set to increase from USD 818 billion in 2015 to USD 2 trillion by 2030.

To address this growing public health crisis, it is very important to identify the failure rate of various available drugs and treatments which are slowing down the progression of Alzheimer's disease.

Since the risk associated with drugs for Alzheimer's disease is high, biomarkers have emerged as key advancements, reducing the risk and enhancing therapeutic outcomes. Biomarkers are helping researchers identify key biological events regarding the disease and drugs that are being used in the treatment of Alzheimer's disease.

The use of biomarkers augments the drug development process by reducing risks related to drug development and adding value to the selection of the most optimal drug candidates for large and expensive phase 3 clinical trials. Because of this, the usage of biomarkers is increasing. With the development of novel biomarkers for therapeutic use, the market for Alzheimer’s disease is witnessing growth opportunities in terms of new drug therapy options.

Companies operating in the Alzheimer’s therapeutics market are actively seeking to strengthen their position through acquisitions and mergers, which significantly accelerate the manufacturer’s ability to capture a significant share of the market.

For instance:

  • On April 5 2021, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.

The global Alzheimer’s therapeutics market is expected to record sales worth US$ 2.8 Bn in the year 2022 and is set to expand at a CAGR of 9.3% over the forecast period (2022-2032).

Sales Analysis of Alzheimer’s Therapeutics from 2017 to 2021 Vs Market Outlook for 2022 to 2032

The sale of Alzheimer’s therapeutics expanded at a CAGR of 6.5% from 2017 to 2021 owing to the increased adoption of generic drugs like Donepezil by people, increasing use of biomarkers in Alzheimer’s diagnosis and drug development.

Many research activities regarding the development of diagnostic technologies are ongoing in the world for the treatment of Alzheimer’s. In addition to the traditional treatment therapies, new technologies are assisting in the diagnosis and treatment of Alzheimer's disease. New diagnostic criteria are helping to identify the validated diagnostic biomarkers. Increasing healthcare awareness and new diagnostic technologies for Alzheimer’s disease are fuelling the growth of the global Alzheimer’s disease therapeutics market in the forecast period.

According to the National Institute of Aging, researchers have identified more than 25 genes, which are additional genes involved in Alzheimer's disease and play a role in the treatment of the disease. By finding out these pathways, researchers are identifying possible targets for drugs and non-drug interventions to stop or prevent the disease.

Alzheimer’s Therapeutics Market Download Report Brochure

For instance, genes involved in the treatment of inflammation have recently been found to be associated with Alzheimer’s and can serve as therapeutic targets in the near future.

Many new technologies are being used to monitor Alzheimer's disease and to detect its progression over time, which guides individuals in maintaining and tracking their activities. Increasing R&D spending and ongoing development of new therapies to treat, delay, and prevent the disease, as well as early diagnosis of the condition is creating an array of opportunities in the market for Alzheimer’s Therapeutics.

Thus, offers a great opportunity for the manufacturers of the industry to grow at a CAGR of 9.3% from 2022 to 2032 globally.

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Key Opportunities for Alzheimer’s Therapeutics Kits Manufacturers?

In terms of Alzheimer’s, there has been an increase in the applications of various machine learning approaches, most commonly with imaging data for diagnosis and disease progression. This includes amyloid PET imaging, combined PET and MR imaging, and spectral phenotyping, among others.

For example, researchers from VA Bedford and VA Boston healthcare systems developed a non-invasive optical technique that helps detect the condition of Alzheimer’s disease. This new technique uses spectroscopy to identify structural changes in the brain.

This technological advancement has evolved to address the needs of people with dementia, informal caregivers, formal caregivers and social caregivers, and created a huge opportunity in the Alzheimer’s therapeutics market.

In terms of the impact of the aduhelm drug, the pressure has increased on the government-funded health programs such as Medicare for the elder population and Medicaid for low-income families, as millions of Americans lost their employer-sponsored health insurance. Medicare is expected to be hit the hardest since most Alzheimer's patients are over 65 years of age.

The expected budget for Alzheimer’s therapeutics is to be double as compared to the budget for all other physician-administered drugs. Furthermore, payment for expensive brain scans associated with a diagnosis of Alzheimer's payment is still not clear. coverage policy, when it emerges, could necessarily limit treatment usage - and private insurers are likely to follow suit. Thus the drug is expected to increase insurance premiums and increase out of pocket costs.

All the above scenarios offer a great opportunity for market growth during the forecast period from 2022 to 2032.

What are the Factors Restraining Demand for Alzheimer’s Therapeutics?

Many Alzheimer’s therapies have been discontinued in recent years, such as drugs like donepezil and others. According to the National Library of Medicine, in 2021, donepezil showed adverse effects on the patients, which is the primary reason for its discontinuation.

This rate of discontinuation is increasing because of the lack of improvement in cognitive function, very less efficacy on Alzheimer's disease symptomatology and the lack of a reliable safety profile of the drugs used in the treatment. This factor is contributing to the high discontinuation rates of current therapies due to their side effects, which is restraining the growth of the Alzheimer’s therapeutics market during the forecast period.

Stigma associated with Alzheimer’s disease remains a major barrier in the diagnosis and overall prognosis of Alzheimer’s disease. Self-stigma and societal stigma are hampering the diagnosis pathway.

In some regions, there are false beliefs regarding the treatment and diagnosis of Alzheimer’s, which is adding fuel to the stigma. Delay in seeking help is also one of the factors causing a delay in the treatment and diagnosis of the disease which is one of the major factor to hamper the market growth.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Country-wise Insights

What Makes the U.S. the Largest Market for Alzheimer’s Therapeutics?

The U.S. rules the North American region with a total market share of about 93.4% in 2021 and is expected to experience the same growth throughout the forecast period. The U.S. is the most lucrative market for Alzheimer’s therapeutics owing to the rise in prevalence of Alzheimer’s disease and other types of dementia in the region as well as a huge investment in research and development activities, and the launch of new products in the region.

For instance, according to the Journal of the Alzheimer’s Association, In the U.S., About 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer’s dementia. approximately, 5.0% of the population aged 65-74, 13.1% of the population aged 75-84, and 33.2% of the population aged 85 and older have Alzheimer’s dementia.

Why Germany is considered a Lucrative Market for Alzheimer’s therapeutics in Europe?

Germany is set to exhibit a CAGR of nearly 21.6% in the European Alzheimer’s therapeutics market during the forecast period owing to an increase in the elderly population, an escalation in healthcare expenditure, and increasing funding from the government.

According to the Journal of the Alzheimer’s Association, In Germany, about more than 1.5 million people are living presently with Alzheimer’s disease.

Additionally, increasing life expectancy in Germany and other parts of Europe boosts the market to grow forward during the forecast period from 2022 to 2032 in the region.

What Makes China an Emerging Market for Alzheimer’s Therapeutics?

China holds a 41.2% share in the East Asia Alzheimer’s therapeutics market in 2021 and is projected to increase at a high CAGR rate of 12.2% during the forecast period. This growth is associated with rapidly improving medical infrastructure, increasing scientific studies associated with the treatment and monitoring of Alzheimer's disease, as well as significant government and private sector funding in the country's Alzheimer's research is driving the market growth during the forecast years in China.

Category-wise Insights

Which Alzheimer’s therapeutics drug is driving market growth?

Donepezil project lucrative growth at a CAGR of 9.2% till the end of the forecast period, with a market share of around 68.4% in 2021. The administration of donepezil improves the cognitive function in patients for up to 52 weeks with Alzheimer’s disease without increasing the risk of clinically significant safety events, which makes it the most lucrative drug in all the drugs of Alzheimer’s disease.

Which Drug class is Large of Focus in the Alzheimer’s Therapeutics Market?

Cholinesterase Inhibitors hold a revenue share of 90.9% in 2021 and are expected to hold a similar share over the forecast period at a CAGR of 9.2% in 2021.

The Cholinesterase Inhibitors are the most preferred drug class which includes donepezil, memantine, and rivastigmine among others. Cholinesterase inhibitors functions in the peripheral nervous system and the central nervous system associated with the disease and work as the most effective treatment.

This factor makes it the most preferred drug class and thus it is expected to boost the market during the forecast period from 2022 to 2032.

Which Distribution Channel Benefits the Most by Employment of Alzheimer’s Therapeutics?

Hospitals are the leading segment in the Alzheimer’s therapeutics market with a 33.8% market share in 2021 and are expected to hold a similar share over the forecast period growing at a CAGR of 10.5% in 2021 due to the easy access and availability of drugs and therapies for Alzheimer’s treatment.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competitive Landscape

Key players in the Alzheimer’s therapeutics market are actively focusing on collaboration, product launch, and expansion to gain a strong position in the market.

These strategies will help market players to enhance their product portfolio together with market penetration. Thereby, increasing their overall revenue share in the global Alzheimer’s therapeutics market.

Given below are a few examples of the key strategies followed by the manufacturers:

  • March 2019, Zydus Cadila received US FDA approval to market its Rivastigmine transdermal system, used in the treatment of Alzheimer's disease
  • In September 2017, Zydus received approval from U.S. FDA for Donepezil hydrochloride tablets which are used for the treatment of dementia of the Alzheimer’s type.
  • In March 2022, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer’s disease

Similarly, recent developments related to companies manufacturing Alzheimer’s therapeutics products have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as per Alzheimer’s Therapeutics Industry Analysis

Attribute

Details

Forecast Period

2017-2021

Historical Data Available for

2022-2032

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa

Key Countries Covered

US, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Nordic countries, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Philippines, Indonesia, Vietnam, Australia, New Zealand, GCC countries, Israel, Turkey, South Africa and North Africa.

Key Market Segments Covered

Drug Name, Drug Class, Distribution Channel and Region

Key Companies Profiled

  • AbbVie, Inc.
  • Teva Pharmaceuticals Ltd.
  • Eisai Co., Ltd.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Novartis AG
  • Zydus Lifesciences Ltd (CADILA)
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Aurobindo Pharma Ltd
  • Amneal Pharmaceuticals Inc.
  • Macleods Pharmaceuticals Ltd.
  • Viatris Inc.
  • Lupin Ltd
  • Cipla Ltd.
  • Torrent pharmaceuticals ltd.
  • Unichem laboratories ltd
  • Lannett Inc.

Pricing

Available upon Request

Key Market Segments Covered in Alzheimer’s Therapeutics Industry Research

By Drug Name:

  • Donepezil
  • Rivastigmine
  • Memantine
  • Galantamine
  • Manufactured combination of memantine and donepezil

By Drug Class:

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Manufactured Combination

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

The global Alzheimer’s therapeutics market is worth US$ 2.6 Bn in 2021 and is set to expand 2.4X over the next ten years.

From 2017-2021, the market for Alzheimer’s therapeutics expanded at the rate of 6.5%, owing to an increasing pool of Alzheimer’s patients across the globe.

The Alzheimer’s therapeutics market is expected to reach US$ 6.8 Bn by the end of 2032, with sales revenue expected to register a CAGR of 9.3%.

The U.S., Germany, U.K., China and France are the top five countries that are expected to drive demand for the Alzheimer’s therapeutics industry.

North America is one of the key markets for Alzheimer’s therapeutics, with the U.S. expected to account for nearly 93.4% of the North American market in the year 2021.

Demand for Alzheimer’s therapeutics in Europe is expected to register a growth of 9.3% over the next ten years.

The U.S., Germany and U.K. are key producers of Alzheimer’s therapeutics products.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Innovation / Development Trends

4. Key Success Factors

    4.1. Treatment Regime

    4.2. Disease epidemiology of Alzheimer’s disease

    4.3. Product Adoption/ Usage Analysis, by region

    4.4. Recent Product Approval 

    4.5. Key Promotional Strategies by Market Players

    4.6. Regulatory Scenario

    4.7. Pipeline Assessment

    4.8. Porter’s Analysis

    4.9. PESTLE Analysis

    4.10. Supply Chain Analysis

    4.11. Dosage Patterns

    4.12. Impact of Aduhelm Drug

5. Global Alzheimer’s Therapeutics Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

    5.1. Historical Market Value (US$ Mn) Analysis, 2017–2021

    5.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global Healthcare Spending Overview

        6.1.2. Global Pharmaceutical Market Outlook

        6.1.3. Global Prevalence of Dementia

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Rising ageing population

        6.2.2. Growing investment in healthcare expenditure

        6.2.3. Growing advancements in diagnostic technologies

        6.2.4. Rising prevalence of neurodegenerative disease

        6.2.5. Adverse effects may impact the market growth

        6.2.6. Key Strategic Developments

        6.2.7. Product Adoption Rate and Demand

        6.2.8. New Product Launches

    6.3. COVID-19 Crisis – Impact Assessment

        6.3.1. COVID-19 Crisis Analysis

        6.3.2. Current GDP Projection and Probable Impact

        6.3.3. Short-Mid-Long Term Outlook 

        6.3.4. Impact of COVID-19 on caregivers of Alzheimer’s disease

        6.3.5. Impact of COVID-19 on Alzheimer’s disease diagnosis

    6.4. Market Dynamics

        6.4.1. Drivers

        6.4.2. Restraints

        6.4.3. Opportunity Analysis

    6.5. Global Supply Demand Analysis

7. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Name

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis, By Drug Name, 2017–2021

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Name, 2022–2032

        7.3.1. Donepezil

        7.3.2. Rivastigmine

        7.3.3. Memantine

        7.3.4. Galantamine

        7.3.5. Manufactured Combination of memantine and donepezil

    7.4. Market Attractiveness Analysis, By Drug Name

8. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Class 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2017–2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2022–2032

        8.3.1. Cholinesterase Inhibitors

        8.3.2. NMDA Receptor Antagonists 

        8.3.3. Manufactured Combination

    8.4. Market Attractiveness Analysis, By Drug Class 

9. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2017–2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2022–2032

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Drug Stores

        9.3.4. Online Pharmacies

    9.4. Market Attractiveness Analysis, By Distribution Channel

10. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2017–2021

    10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2022–2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis, By Region

11. North America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    11.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

        11.3.1. By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Name

        11.3.3. By Drug Class

        11.3.4. By Distribution Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Drug Name

        11.4.3. By Drug Class

        11.4.4. By Distribution Channel

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

    11.7. Country Level Analysis & Forecast

        11.7.1. U.S. Alzheimer’s Therapeutics Market Analysis

            11.7.1.1. Introduction

            11.7.1.2. Market Analysis and Forecast, By Market Taxonomy

                11.7.1.2.1. By Drug Name

                11.7.1.2.2. By Drug Class

                11.7.1.2.3. By Distribution Channel

        11.7.2. Canada Alzheimer’s Therapeutics Market Analysis

            11.7.2.1. Introduction

            11.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                11.7.2.2.1. By Drug Name

                11.7.2.2.2. By Drug Class

                11.7.2.2.3. By Distribution Channel

12. Latin America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    12.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

        12.3.1. By Country

            12.3.1.1. Mexico

            12.3.1.2. Brazil

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Name

        12.3.3. By Drug Class

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Drug Name

        12.4.3. By Drug Class

        12.4.4. By Distribution Channel

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

    12.7. Country Level Analysis & Forecast

        12.7.1. Mexico Alzheimer’s Therapeutics Market Analysis

            12.7.1.1. Introduction

            12.7.1.2. Market Analysis and Forecast, By Market Taxonomy

                12.7.1.2.1. By Drug Name

                12.7.1.2.2. By Drug Class

                12.7.1.2.3. By Distribution Channel

        12.7.2. Brazil Alzheimer’s Therapeutics Market Analysis

            12.7.2.1. Introduction

            12.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                12.7.2.2.1. By Drug Name

                12.7.2.2.2. By Drug Class

                12.7.2.2.3. By Distribution Channel

        12.7.3. Argentina Alzheimer’s Therapeutics Market Analysis

            12.7.3.1. Introduction

            12.7.3.2. Market Analysis and Forecast, By Market Taxonomy

                12.7.3.2.1. By Drug Name

                12.7.3.2.2. By Drug Class

                12.7.3.2.3. By Distribution Channel

13. Europe Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    13.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Nordic Countries

            13.3.1.8. Russia

            13.3.1.9. Rest of Europe

        13.3.2. By Country

        13.3.3. By Drug Name

        13.3.4. By Drug Class

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug Name

        13.4.3. By Drug Class

        13.4.4. By Distribution Channel

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

    13.7. Country Level Analysis & Forecast

        13.7.1. Germany Alzheimer’s Therapeutics Market Analysis

            13.7.1.1. Introduction

            13.7.1.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.1.2.1. By Drug Name

                13.7.1.2.2. By Drug Class

                13.7.1.2.3. By Distribution Channel

        13.7.2. Italy Alzheimer’s Therapeutics Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.2.2.1. By Drug Name

                13.7.2.2.2. By Drug Class

                13.7.2.2.3. By Distribution Channel

        13.7.3. France Alzheimer’s Therapeutics Market Analysis

            13.7.3.1. Introduction

            13.7.3.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.3.2.1. By Drug Name

                13.7.3.2.2. By Drug Class

                13.7.3.2.3. By Distribution Channel

        13.7.4. U.K. Alzheimer’s Therapeutics Market Analysis

            13.7.4.1. Introduction

            13.7.4.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.4.2.1. By Drug Name

                13.7.4.2.2. By Drug Class

                13.7.4.2.3. By Distribution Channel

        13.7.5. Spain Alzheimer’s Therapeutics Market Analysis

            13.7.5.1. Introduction

            13.7.5.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.5.2.1. By Drug Name

                13.7.5.2.2. By Drug Class

                13.7.5.2.3. By Distribution Channel

        13.7.6. BENELUX Alzheimer’s Therapeutics Market Analysis

            13.7.6.1. Introduction

            13.7.6.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.6.2.1. By Drug Name

                13.7.6.2.2. By Drug Class

                13.7.6.2.3. By Distribution Channel

        13.7.7. Nordic Countries Alzheimer’s Therapeutics Market Analysis

            13.7.7.1. Introduction

            13.7.7.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.7.2.1. By Drug Name

                13.7.7.2.2. By Drug Class

                13.7.7.2.3. By Distribution Channel

        13.7.8. Russia Alzheimer’s Therapeutics Market Analysis

            13.7.8.1. Introduction

            13.7.8.2. Market Analysis and Forecast, By Market Taxonomy

                13.7.8.2.1. By Drug Name

                13.7.8.2.2. By Drug Class

                13.7.8.2.3. By Distribution Channel

14. East Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    14.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Country

        14.3.3. By Drug Name

        14.3.4. By Drug Class

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug Name

        14.4.3. By Drug Class

        14.4.4. By Distribution Channel

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

    14.7. Country Level Analysis & Forecast

        14.7.1. China Alzheimer’s Therapeutics Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast, By Market Taxonomy

                14.7.1.2.1. By Drug Name

                14.7.1.2.2. By Drug Class

                14.7.1.2.3. By Distribution Channel

        14.7.2. Japan Alzheimer’s Therapeutics Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                14.7.2.2.1. By Drug Name

                14.7.2.2.2. By Drug Class

                14.7.2.2.3. By Distribution Channel

        14.7.3. South Korea Alzheimer’s Therapeutics Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast, By Market Taxonomy

                14.7.3.2.1. By Drug Name

                14.7.3.2.2. By Drug Class

                14.7.3.2.3. By Distribution Channel

15. South Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    15.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Malaysia

            15.3.1.4. Philippines

            15.3.1.5. Indonesia

            15.3.1.6. Vietnam

            15.3.1.7. Rest of South Asia

        15.3.2. By Drug Name

        15.3.3. By Drug Class

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug Name

        15.4.3. By Drug Class

        15.4.4. By Distribution Channel

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

    15.7. Country Level Analysis & Forecast

        15.7.1. India Alzheimer’s Therapeutics Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.1.2.1. By Drug Name

                15.7.1.2.2. By Drug Class

                15.7.1.2.3. By Distribution Channel

        15.7.2. Thailand Alzheimer’s Therapeutics Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.2.2.1. By Drug Name

                15.7.2.2.2. By Drug Class

                15.7.2.2.3. By Distribution Channel

        15.7.3. Malaysia Alzheimer’s Therapeutics Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.3.2.1. By Drug Name

                15.7.3.2.2. By Drug Class

                15.7.3.2.3. By Distribution Channel

        15.7.4. Philippines Alzheimer’s Therapeutics Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.4.2.1. By Drug Name

                15.7.4.2.2. By Drug Class

                15.7.4.2.3. By Distribution Channel

        15.7.5. Indonesia Alzheimer’s Therapeutics Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.5.2.1. By Drug Name

                15.7.5.2.2. By Drug Class

                15.7.5.2.3. By Distribution Channel

        15.7.6. Vietnam Alzheimer’s Therapeutics Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.6.2.1. By Drug Name

                15.7.6.2.2. By Drug Class

                15.7.6.2.3. By Distribution Channel

        15.7.7. Rest of South Asia Alzheimer’s Therapeutics Market Analysis

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast, By Market Taxonomy

                15.7.7.2.1. By Drug Name

                15.7.7.2.2. By Drug Class

                15.7.7.2.3. By Distribution Channel

16. Oceania Alzheimer’s Therapeutics Market 2017-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    16.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

                   16.3.1. By Country

                    16.3.2. Australia

                    16.3.3. New Zealand

                16.3.4. By Drug Name

                16.3.5.  By Drug Class

                16.3.6. By Distribution Channel

    16.4. Market Attractiveness Analysis

                16.4.1. By Country

                16.4.2. By Drug Name

                16.4.3. By Drug Class

                16.4.4. By Distribution Channel

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

    16.7. Country Level Analysis & Forecast

                16.7.1. Australia Alzheimer’s Therapeutics Market Analysis

                    16.7.2.Introduction

                    16.7.3. Market Analysis and Forecast, By Market Taxonomy

                            16.7.3.1. By Drug Name

                            16.7.3.2.By Drug Class

                            16.7.3.3. By Distribution Channel

                16.7.2. New Zealand Alzheimer’s Therapeutics Market Analysis

                    16.7.2.1. Introduction

                    16.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                            16.7.2.2.1. By Drug Name

                            16.7.2.2.2. By Drug Class

                            16.7.2.2.3. By Distribution Channel

17. Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021

    17.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Israel

            17.3.1.3. Turkey

            17.3.1.4. South Africa 

            17.3.1.5. North Africa

            17.3.1.6. Rest of Middle East and Africa

        17.3.2. By Drug Name

        17.3.3. By Drug Class

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug Name

        17.4.3. By Drug Class

        17.4.4. By Distribution Channel

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country Level Analysis & Forecast

        17.7.1. GCC Countries Alzheimer’s Therapeutics Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast, By Market Taxonomy

                17.7.1.2.1. By Drug Name

                17.7.1.2.2. By Drug Class

                17.7.1.2.3. By Distribution Channel

        17.7.2. Israel Alzheimer’s Therapeutics Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast, By Market Taxonomy

                17.7.2.2.1. By Drug Name

                17.7.2.2.2. By Drug Class

                17.7.2.2.3. By Distribution Channel

        17.7.3. Turkey Alzheimer’s Therapeutics Market Analysis

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast, By Market Taxonomy

                17.7.3.2.1. By Drug Name

                17.7.3.2.2. By Drug Class

                17.7.3.2.3. By Distribution Channel

        17.7.4. South Africa Alzheimer’s Therapeutics Market Analysis

            17.7.4.1. Introduction

            17.7.4.2. Market Analysis and Forecast, By Market Taxonomy

                17.7.4.2.1. By Drug Name

                17.7.4.2.2. By Drug Class

                17.7.4.2.3. By Distribution Channel

        17.7.5. North Africa Alzheimer’s Therapeutics Market Analysis

            17.7.5.1. Introduction

            17.7.5.2. Market Analysis and Forecast, By Market Taxonomy

                17.7.5.2.1. By Drug Name

                17.7.5.2.2. By Drug Class

                17.7.5.2.3. By Distribution Channel

        17.7.6. Rest of MEA Alzheimer’s Therapeutics Market Analysis

            17.7.6.1. Introduction

            17.7.6.2. Market Analysis and Forecast, By Market Taxonomy

                17.7.6.2.1. By Drug Name

                17.7.6.2.2. By Drug Class

                17.7.6.2.3. By Distribution Channel

18. Market Structure Analysis

    18.1. Market Analysis, By Tier of Companies

    18.2. Market Share Analysis of Top Players

    18.3. Market Presence Analysis

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Key Development Analysis

    19.3. Competition Benchmarking

    19.4. Competition Deep Dive 

        19.4.1. Biogen Inc. 

            19.4.1.1. Overview

            19.4.1.2. Product Portfolio

            19.4.1.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.1.4. Sales Footprint

            19.4.1.5. Strategy Overview

        19.4.2. AbbVie, Inc.

            19.4.2.1. Overview

            19.4.2.2. Product Portfolio

            19.4.2.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.2.4. Sales Footprint

            19.4.2.5. Strategy Overview

        19.4.3. Teva Pharmaceuticals Ltd.

            19.4.3.1. Overview

            19.4.3.2. Product Portfolio

            19.4.3.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.3.4. Sales Footprint

            19.4.3.5. Strategy Overview

        19.4.4. Eisai Co., Ltd.

            19.4.4.1. Overview

            19.4.4.2. Product Portfolio

            19.4.4.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.4.4. Sales Footprint

            19.4.4.5. Strategy Overview

        19.4.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            19.4.5.1. Overview

            19.4.5.2. Product Portfolio

            19.4.5.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.5.4. Sales Footprint

            19.4.5.5. Strategy Overview

        19.4.6. Novartis AG

            19.4.6.1. Overview

            19.4.6.2. Product Portfolio

            19.4.6.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.6.4. Sales Footprint

            19.4.6.5. Strategy Overview

        19.4.7. Zydus Lifesciences Ltd (CADILA)

            19.4.7.1. Overview

            19.4.7.2. Product Portfolio

            19.4.7.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.7.4. Sales Footprint

            19.4.7.5. Strategy Overview

        19.4.8. Sun Pharmaceutical Industries Ltd.

            19.4.8.1. Overview

            19.4.8.2. Product Portfolio

            19.4.8.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.8.4. Sales Footprint

            19.4.8.5. Strategy Overview

        19.4.9. Dr. Reddy's Laboratories Ltd

            19.4.9.1. Overview

            19.4.9.2. Product Portfolio

            19.4.9.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.9.4. Sales Footprint

            19.4.9.5. Strategy Overview

        19.4.10. Aurobindo Pharma Ltd

            19.4.10.1. Overview

            19.4.10.2. Product Portfolio

            19.4.10.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.10.4. Sales Footprint

            19.4.10.5. Strategy Overview

        19.4.11. Amneal Pharmaceuticals Inc.

            19.4.11.1. Overview

            19.4.11.2. Product Portfolio

            19.4.11.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.11.4. Sales Footprint

            19.4.11.5. Strategy Overview

        19.4.12. Macleods Pharmaceuticals Ltd.

            19.4.12.1. Overview

            19.4.12.2. Product Portfolio

            19.4.12.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.12.4. Sales Footprint

            19.4.12.5. Strategy Overview

        19.4.13. Viatris Inc.

            19.4.13.1. Overview

            19.4.13.2. Product Portfolio

            19.4.13.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.13.4. Sales Footprint

            19.4.13.5. Strategy Overview

        19.4.14. Lupin Ltd

            19.4.14.1. Overview

            19.4.14.2. Product Portfolio

            19.4.14.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.14.4. Sales Footprint

            19.4.14.5. Strategy Overview

        19.4.15. Cipla Ltd.

            19.4.15.1. Overview

            19.4.15.2. Product Portfolio

            19.4.15.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.15.4. Sales Footprint

            19.4.15.5. Strategy Overview

        19.4.16. Torrent pharmaceuticals ltd.

            19.4.16.1. Overview

            19.4.16.2. Product Portfolio

            19.4.16.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.16.4. Sales Footprint

            19.4.16.5. Strategy Overview

        19.4.17. Unichem laboratories ltd

            19.4.17.1. Overview

            19.4.17.2. Product Portfolio

            19.4.17.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.17.4. Sales Footprint

            19.4.17.5. Strategy Overview

        19.4.18. Lannett Inc.

            19.4.18.1. Overview

            19.4.18.2. Product Portfolio

            19.4.18.3. Profitability by Market Segments (Product/Channel/Region)

            19.4.18.4. Sales Footprint

            19.4.18.5. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Name

Table 02: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 03: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

Table 04: Global Alzheimer’s Therapeutics Market Size (US$ Mn) Analysis 2017–2021 and Forecast 2022–2032, By Region

Table 05: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 06: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 07: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 08: North America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 

Table 09: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 10: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 11: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 12: Latin America Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 

Table 13: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 14: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 15: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 16: Europe Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 

Table 17: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 18: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 19: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 20: East Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 

Table 21: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 22: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 23: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 24: South Asia Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 

Table 25: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 26: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 27: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 28: Oceania Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel 

Table 29: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Country

Table 30: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Name 

Table 31: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Drug Class

Table 32: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Size Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 02: Global Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 03: Global Alzheimer’s Therapeutics Market Absolute $ Opportunity, 2021–2032

Figure 04: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Drug Name, 2022 & 2032

Figure 05: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Drug Name, 2022–2032

Figure 06: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 07: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Drug Class, 2022 & 2032

Figure 08: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Drug Class, 2022–2032

Figure 09: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 10: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Distribution Channel, 2022 & 2032

Figure 11: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Distribution Channel, 2022–2032

Figure 12: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 13: Global Alzheimer’s Therapeutics Market Share Analysis (%), By Region, 2022 & 2032

Figure 14: Global Alzheimer’s Therapeutics Market Y-o-Y Analysis (%), By Region, 2022–2032

Figure 15: Global Alzheimer’s Therapeutics Market Attractiveness Analysis By Region, 2022–2032

Figure 16: North America Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 17: North America Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 18: North America Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 19: North America Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 20: North America Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 21: North America Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 22: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 23: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 24: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 25: North America Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 26: U.S Market Value Proportion Analysis, 2022

Figure 27: Global Vs. U.S Growth Comparison, 2022-2032

Figure 28: U.S. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 29: U.S. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 30: U.S. Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 31: Canada Market Value Proportion Analysis, 2022

Figure 32: Global Vs. Canada Growth Comparison, 2022-2032

Figure 33: Canada Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 34: Canada Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 35: Canada Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 36: Latin America Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 37: Latin America Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 38: Latin America Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 39: Latin America Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 40: Latin America Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 41: Latin America Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 42: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 43: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 44: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 45: Latin America Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 46: Mexico Market Value Proportion Analysis, 2022

Figure 47: Global Vs. Mexico Growth Comparison, 2022-2032

Figure 48: Mexico Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 49: Mexico Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 50: Mexico Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 51: Brazil Market Value Proportion Analysis, 2022

Figure 52: Global Vs. Brazil Growth Comparison, 2022-2032

Figure 53: Brazil Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 54: Brazil Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 55: Brazil Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 56: Argentina Market Value Proportion Analysis, 2022

Figure 57: Global Vs. Argentina Growth Comparison, 2022-2032

Figure 58: Argentina Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 59: Argentina Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 60: Argentina Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 61: Europe Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 62: Europe Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 63: Europe Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 64: Europe Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 65: Europe Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 66: Europe Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 67: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 68: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 69: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 70: Europe Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 71: Germany Market Value Proportion Analysis, 2022

Figure 72: Global Vs. Germany Growth Comparison, 2022-2032

Figure 73: Germany Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 74: Germany Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 75: Germany Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 76: Italy Market Value Proportion Analysis, 2022

Figure 77: Global Vs. Italy Growth Comparison, 2022-2032

Figure 78: Italy Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 79: Italy Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 80: Italy Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 81: France Market Value Proportion Analysis, 2022

Figure 82: Global Vs. France Growth Comparison, 2022-2032

Figure 83: France Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 84: France Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 85: France Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 86: U.K. Market Value Proportion Analysis, 2022

Figure 87: Global Vs. U.K. Growth Comparison, 2022-2032

Figure 88: U.K. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 89: U.K. Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 90: U.K. Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 91: Spain Market Value Proportion Analysis, 2022

Figure 92: Global Vs. Spain Growth Comparison, 2022-2032

Figure 93: Spain Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 94: Spain Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 95: Spain Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 96: BENELUX Market Value Proportion Analysis, 2022

Figure 97: Global Vs. BENELUX Growth Comparison, 2022-2032

Figure 98: BENELUX Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 99: BENELUX Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 100: BENELUX Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 101: Nordic Countries Market Value Proportion Analysis, 2022

Figure 102: Global Vs. Nordic Countries Growth Comparison, 2022-2032

Figure 103: Nordic Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 104: Nordic Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 105: Nordic Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 106: Russia Market Value Proportion Analysis, 2022

Figure 107: Global Vs. Russia Growth Comparison, 2022-2032

Figure 108: Russia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 109: Russia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 110: Russia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 111: East Asia Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 112: East Asia Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 113: East Asia Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 114: East Asia Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 115: East Asia Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 116: East Asia Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 117: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 118: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 119: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 120: East Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 121: China Market Value Proportion Analysis, 2022

Figure 122: Global Vs. China Growth Comparison, 2022-2032

Figure 123: China Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 124: China Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 125: China Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 126: Japan Market Value Proportion Analysis, 2022

Figure 127: Global Vs. Japan Growth Comparison, 2022-2032

Figure 128: Japan Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 129: Japan Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 130: Japan Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 131: South Korea Market Value Proportion Analysis, 2022

Figure 132: Global Vs. South Korea Growth Comparison, 2022-2032

Figure 133: South Korea Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 134: South Korea Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 135: South Korea Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 136: South Asia Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 137: South Asia Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 138: South Asia Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 139: South Asia Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 140: South Asia Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 141: South Asia Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 142: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 143: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 144: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 145: South Asia Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 146: India Market Value Proportion Analysis, 2022

Figure 147: Global Vs. India Growth Comparison, 2022-2032

Figure 148: India Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 149: India Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 150: India Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 151: Thailand Market Value Proportion Analysis, 2022

Figure 152: Global Vs. Thailand Growth Comparison, 2022-2032

Figure 153: Thailand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 154: Thailand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 155: Thailand Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 156: Malaysia Market Value Proportion Analysis, 2022

Figure 157: Global Vs. Malaysia Growth Comparison, 2022-2032

Figure 158: Malaysia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 159: Malaysia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 160: Malaysia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 161: Philippines Market Value Proportion Analysis, 2022

Figure 162: Global Vs. Philippines Growth Comparison, 2022-2032

Figure 163: Philippines Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 164: Philippines Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 165: Philippines Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 166: Indonesia Market Value Proportion Analysis, 2022

Figure 167: Global Vs. Indonesia Growth Comparison, 2022-2032

Figure 168: Indonesia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 169: Indonesia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 170: Indonesia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 171: Vietnam Market Value Proportion Analysis, 2022

Figure 172: Global Vs. Vietnam Growth Comparison, 2022-2032

Figure 173: Vietnam Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 174: Vietnam Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 175: Vietnam Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 176: Oceania Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 177: Oceania Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 178: Oceania Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 179: Oceania Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 180: Oceania Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 181: Oceania Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 182: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 183: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 184: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 185: Oceania Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 186: Australia Market Value Proportion Analysis, 2022

Figure 187: Global Vs. Australia Growth Comparison, 2022-2032

Figure 188: Australia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 189: Australia Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 190: Australia Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 191: New Zealand Market Value Proportion Analysis, 2022

Figure 192: Global Vs. New Zealand Growth Comparison, 2022-2032

Figure 193: New Zealand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 194: New Zealand Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 195: New Zealand Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 196: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Country, 2022 (E)

Figure 197: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Drug Name, 2022 (E)

Figure 198: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Drug Class, 2022 (E)

Figure 199: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Split By Distribution Channel, 2022 (E)

Figure 200: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Value Analysis (US$ Mn), 2017–2021

Figure 201: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Value Forecast (US$ Mn), 2021–2032

Figure 202: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Name, 2022–2032

Figure 203: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Drug Class, 2022–2032

Figure 204: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Distribution Channel, 2022–2032

Figure 205: Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Attractiveness Analysis By Country, 2022-2032

Figure 206: GCC Countries Market Value Proportion Analysis, 2022

Figure 207: Global Vs. GCC Countries Growth Comparison, 2022-2032

Figure 208: GCC Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 209: GCC Countries Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 210: GCC Countries  Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 211: Israel Market Value Proportion Analysis, 2022

Figure 212: Global Vs. Israel Growth Comparison, 2022-2032

Figure 213: Israel Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 214: Israel Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 215: Israel Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 216: Turkey Market Value Proportion Analysis, 2022

Figure 217: Global Vs. Turkey Growth Comparison, 2022-2032

Figure 218: Turkey Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 219: Turkey Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 220: Turkey Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 221: South Africa Market Value Proportion Analysis, 2022

Figure 222: Global Vs. South Africa Growth Comparison, 2022-2032

Figure 223: South Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 224: South Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 225: South Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Figure 226: North Africa Market Value Proportion Analysis, 2022

Figure 227: Global Vs. North Africa Growth Comparison, 2022-2032

Figure 228: North Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Name, 2022 & 2032

Figure 229: North Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Drug Class, 2022 & 2032

Figure 230: North Africa Alzheimer’s Therapeutics Market Share Analysis (%) By Distribution Channel, 2022 & 2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Bacteriophage Market

Published : April 2022

Healthcare

Neurological Biomarkers Market

Published : December 2021

Healthcare

Rare Neurological Disease Treatment Market

Published : March 2018

Healthcare

Branded Generics Market

Published : August 2021

Google translate

Alzheimer’s Therapeutics Market